These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32079737)

  • 21. Intravenous Thrombolysis in Patients with Acute Ischemic Stroke after a Reversal of Dabigatran Anticoagulation with Idarucizumab: A Real-World Clinical Experience.
    Šaňák D; Jakubíček S; Černík D; Herzig R; Kunáš Z; Mikulík R; Ostrý S; Reif M; Rohan V; Tomek A; Veverka T
    J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):2479-2483. PubMed ID: 29807757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program.
    Fanikos J; Murwin D; Gruenenfelder F; Tartakovsky I; França LR; Reilly PA; Kermer P; Wowern FV; Lane DA; Butcher K
    Thromb Haemost; 2020 Jan; 120(1):27-35. PubMed ID: 31470445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Systemic thrombolysis after the administration of idarucizumab in acute ischemic stroke].
    Pásztor M; Bereczki D; Szakács Z; May Z
    Ideggyogy Sz; 2017 Jul; 70(7-8):284-288. PubMed ID: 29870643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report.
    Ohtani T; Sintoku R; Yajima T; Kaneko N
    J Med Case Rep; 2019 Dec; 13(1):390. PubMed ID: 31875786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Standard operating procedure for idarucizumab reversal of dabigatran anticoagulation in ischemic and hemorrhagic stroke.
    Frol S; Oblak JP; Šabovič M; Kermer P
    J Thromb Thrombolysis; 2023 Apr; 55(3):506-518. PubMed ID: 36738375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombolytic Therapy in Severe Cardioembolic Stroke After Reversal of Dabigatran with Idarucizumab: Case Report and Literature Review.
    Ohya Y; Makihara N; Wakisaka K; Morita T; Ago T; Kitazono T; Takaba H
    J Stroke Cerebrovasc Dis; 2018 Jul; 27(7):e128-e131. PubMed ID: 29555397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Idarucizumab for Reversal of Dabigatran: Single-Center Real-World Experience.
    Sheikh-Taha M
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):59-64. PubMed ID: 30203330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute stroke thrombolysis following dabigatran reversal using idarucizumab.
    Harsha KJ; Thirunavukkarasu S; Butcher K
    Neurol India; 2019; 67(2):568-570. PubMed ID: 31085880
    [No Abstract]   [Full Text] [Related]  

  • 29. Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis.
    Ng FC; Bice J; Rodda A; Lee-Archer M; Crompton DE
    J Neurol; 2017 Mar; 264(3):591-594. PubMed ID: 28168523
    [No Abstract]   [Full Text] [Related]  

  • 30. Idarucizumab for Reversal of Dabigatran in Early/Emergency Surgeries: A Case Series.
    Peacock WF; Grotta JC; Steiner T
    J Emerg Med; 2019 Dec; 57(6):e167-e173. PubMed ID: 31662218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous Thrombolysis With Recombinant Tissue-Type Plasminogen Activator in a Stroke Patient Receiving Dabigatran Anticoagulant After Antagonization With Idarucizumab.
    Berrouschot J; Stoll A; Hogh T; Eschenfelder CC
    Stroke; 2016 Jul; 47(7):1936-8. PubMed ID: 27301937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dabigatran reversal by idarucizumab in the setting of intracranial hemorrhage: A systematic review of the literature.
    Lu VM; Phan K; Rao PJ; Sharma SV; Kasper EM
    Clin Neurol Neurosurg; 2019 Jun; 181():76-81. PubMed ID: 31015061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous thrombolysis for stroke after Dabigatran reversal with Idarucizumab: an update.
    Cappellari M; Forlivesi S; Squintani GM; Facchinetti R; Bovi P
    J Thromb Thrombolysis; 2017 May; 43(4):528-529. PubMed ID: 28214949
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment With Intravenous Alteplase for Acute Ischemic Stroke After Reversal of Dabigatran With Idarucizumab: A Case Study.
    Jala S; O'Brien E
    J Neurosci Nurs; 2019 Feb; 51(1):21-25. PubMed ID: 30489421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world experience with reversal of dabigatran by idarucizumab.
    Haastrup SB; Hellfritzsch M; Nybo M; Hvas AM; Grove EL
    Thromb Res; 2021 Jan; 197():179-184. PubMed ID: 33227654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Thrombolytic Therapy.
    Kikule I; Baborikina A; Haritoncenko I; Karelis G
    Medicina (Kaunas); 2022 Sep; 58(10):. PubMed ID: 36295516
    [No Abstract]   [Full Text] [Related]  

  • 37. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
    Eikelboom JW; van Ryn J; Reilly P; Hylek EM; Elsaesser A; Glund S; Pollack CV; Weitz JI
    J Am Coll Cardiol; 2019 Oct; 74(14):1760-1768. PubMed ID: 31582135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of patients post reversal with idarucizumab.
    Raco V; Ahuja T; Green D
    J Thromb Thrombolysis; 2018 Nov; 46(4):466-472. PubMed ID: 30120649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Idarucizumab elimination of dabigatran minutes before systemic thrombolysis in acute ischemic stroke.
    Schulz JG; Kreps B
    J Neurol Sci; 2016 Nov; 370():44. PubMed ID: 27772783
    [No Abstract]   [Full Text] [Related]  

  • 40. Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a moment to be a pioneer.
    Turine G; Peeters A; Hermans C; Eeckhoudt S; Duprez T
    Acta Neurol Belg; 2017 Sep; 117(3):753-755. PubMed ID: 28138937
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.